381 related articles for article (PubMed ID: 30963603)
21. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
[TBL] [Abstract][Full Text] [Related]
22. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.
Capurro MI; Shi W; Sandal S; Filmus J
J Biol Chem; 2005 Dec; 280(50):41201-6. PubMed ID: 16227623
[TBL] [Abstract][Full Text] [Related]
23. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
[TBL] [Abstract][Full Text] [Related]
25. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
Kwack MH; Choi BY; Sung YK
Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
Quan H; Li B; Yang J
Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
[TBL] [Abstract][Full Text] [Related]
27. Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells.
Saad A; Liet B; Joucla G; Santarelli X; Charpentier J; Claverol S; Grosset CF; Trézéguet V
Biochemistry; 2018 Feb; 57(7):1201-1211. PubMed ID: 29345911
[TBL] [Abstract][Full Text] [Related]
28. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
29. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
30. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway.
Xu L; Li J; Hou N; Han F; Sun X; Li Q
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):688-696. PubMed ID: 38584523
[TBL] [Abstract][Full Text] [Related]
31. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma.
Wang D; Gao Y; Zhang Y; Wang L; Chen G
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31160489
[TBL] [Abstract][Full Text] [Related]
33. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells.
Meng P; Zhang YF; Zhang W; Chen X; Xu T; Hu S; Liang X; Feng M; Yang X; Ho M
Sci Rep; 2021 Jan; 11(1):40. PubMed ID: 33420124
[TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression.
Wang B; Xian J; Zang J; Xiao L; Li Y; Sha M; Shen M
Biochem Biophys Res Commun; 2019 Jan; 509(1):143-147. PubMed ID: 30573358
[TBL] [Abstract][Full Text] [Related]
35. The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma.
Wang P; Tong K; Li Y; Li X; Zhang Y; Gu J; Lei P; Yan S; Hu P
Cell Signal; 2024 Feb; 114():111007. PubMed ID: 38081444
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
37. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
39. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
40. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
